DRUG RESISTANCE UPDATES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2023-08-11 ms7000000365645384 来自北京

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：耐药
经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难

29 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2024-01-11 ms2000000680553522 来自江苏省

投稿命中率:25.0
偏重的研究方向：微生物耐药
经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？

15 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2023-05-08 ms7000000365645384 来自北京

哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态...

37 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2024-03-05 1851f102e3m 来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：耐药
经验分享：以前是review杂志所以IF很高（>20）但知名度一般

2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望

有合适的文章不妨投一篇试试水

11 0

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2023-02-23 科研小帮来自广西

药物耐药性相关方向

37 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2023-08-08 qinss77 来自湖北省

主编陈哲生正在被Bik博士举报

135 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2022-08-07 病毒猎手

审稿速度:2.0 | 投稿命中率:25.0
经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates

47 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2022-08-07 病毒猎手

Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。

50 0

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2020-05-15 olivia999

审稿速度:2.0 | 投稿命中率:25.0
经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。

156 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152283, encodeId=9fa5215228380, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：耐药 经验分享：记录一下过程待参考：提交之后等待编辑处理等了20多天，外审2个月，RRC等编辑处理等了20天，之后被拒，编辑处理效率较低，寻找评审专家较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Fri Aug 11 16:29:54 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2180690, encodeId=5d48218069032, content=投稿命中率:25.0 偏重的研究方向：微生物耐药 经验分享：友友们，这个期刊稿子提交后多久才会到with editior啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8998146928, createdName=ms2000000680553522, createdTime=Thu Jan 11 08:36:00 CST 2024, time=2024-01-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2130940, encodeId=6d51213094058, content=哪位仁兄投稿过这个期刊的Article？可以分享下经验么，manuscript submitted之后，几天可以with editor？目前等了21天还是manuscript submitted状态..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86405402847, createdName=ms7000000365645384, createdTime=Mon May 08 10:44:37 CST 2023, time=2023-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2191122, encodeId=9efe219112222, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：耐药 经验分享：以前是review杂志所以IF很高（>20）但知名度一般 2023年也开始收article（Article文章总体水平还行，但应该到不了20的水平）最后稳定在哪一档次有待观望 有合适的文章不妨投一篇试试水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Tue Mar 05 10:24:58 CST 2024, time=2024-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2116130, encodeId=3dff21161302f, content=药物耐药性相关方向, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230131/26b2bd8fee4a4f8b82ae4707672c735e/901f236ce8ca4e9c8714b0c839e0f0fd.jpg, createdBy=1e8f8124292, createdName=科研小帮, createdTime=Thu Feb 23 16:01:39 CST 2023, time=2023-02-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2151749, encodeId=aaf12151e49d0, content=主编陈哲生正在被Bik博士举报, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Tue Aug 08 11:27:52 CST 2023, time=2023-08-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1237167, encodeId=62df123e167a7, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Drug Resistance Updates于2022年7月，邀请华人教授陈哲生担新主编。陈哲生教授是药物耐受领域的专家，已发表文章400多篇；同时也是27本期刊的编委成员，200多本期刊的peer reviewer。从Web of Science中的数据可以看到，在陈哲生教授担任主编之前，Drug Resistance Updates主要接收的文章类型：Review。据编辑部最新消息：新任主编陈哲生教授上任后，自2022年7月开始，期刊接受论著文章（full-length research articles）投稿！欢迎大家投稿高质量文章至Drug Resistance Updates, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:20 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237168, encodeId=e5cb123e16803, content=Drug Resistance Updates影响因子变化情况：2019-2021近3年影响因子呈逐年递增趋势，JCR2021年影响因子为22.841，JCR2020年影响因子为18.500，JCR2019为11.000，近2年影响因子增长107.6%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 07 23:41:53 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590909, encodeId=4c0f590909a1, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志对内容和语言的要求都非常高，约稿与自荐相结合。主编是个极度认真的人。如果他对你的topic满意，会给机会修改，但是会提很高的要求，直到达到要求为止。如果对topic不满意，直接拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac591869, createdName=olivia999, createdTime=Fri May 15 11:23:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860155, encodeId=bcb186015540, content=审稿速度:1.0 经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=323c5413977, createdName=ms1145759477415829, createdTime=Mon May 04 05:04:15 CST 2020, time=2020-05-04, status=1, ipAttribution=)]

2020-05-04 ms1145759477415829

审稿速度:1.0
经验分享：i submitted 1-2 articles to this journal each year. it takes 1-2 months for reviewing and comments. however, you can not submit articles directly to the journal. in most cases, you should receive an invitation to submit.

130 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务